Cookies: Information & Consent

We have placed cookies on your device to help make this website better. Some of the cookies we use are essential for this site to work. We also use some non-essential cookies to collect information for making reports and to help us improve the site. You will find more detailled information in our Privacy Chart.

March 2020

Banook Group welcomes Turenne Santé as new investor, alongside the management

Funds obtained will enable the European leader in cardiac safety to continue its…
Read the full post
May 2018

Webinar : Advances in cardiovascular diagnostic devices for clinical trial

Tuesday, May 29th, 2018  6:00 PM CEST (Central European Time) UTC/GMT + 2…
Read the full post
April 2017

Event Participation 2017

Banook Group will attend the following exhibitions. Let’s meet there!
Read the full post
February 2017

Cardiabase by Banook Group opens subsidiary in Montreal, Canada

Group strengthens its presence in North American market, aiming for 30% growth in…
Read the full post
March 2015

Banook Group - New branding announcement

Cardiabase/Banook Central Imaging becomes Banook Group - New branding announcement.
Read the full post
March 2014

Webinar: Imaging anti-cancer treatment response at a preclinical and clinical stage

Use of imaging in oncology clinical trials is mainly based on morphological evaluation…
Read the full post
Solutions > Endpoint adjudication


Show Banook Group offers

As per current guidelines, multi-centric studies require:


  • A central review of source data by independent expert teams (adjudication committees, review board, clinical event/endpoint committee…),


  • And uniform procedures for handling trial-related events.


Banook/Cardiabase was awarded its first MACE (Major Adverse Cardiovascular Event) adjudication in 2004, one and two years before the EMA and FDA, respectively, finalized their guidance on this topic. Since then, we have been involved in a large number of endpoint adjudication projects for various therapeutic classes, including anticoagulants, antiarrhythmics, gene therapies, mab, anti-diabetic agents and several medical disorders, including coronary artery disease, heart failure, atrial fibrillation, ventricular arrhythmia, peripheral vascular disease, arthritis, and type 2 diabetes.

Our board of experts supports all aspects of the process from development of clinically relevant definitions and charter development to timely field management of endpoint packages and sophisticated status reports as well as study impact analyses.


To adjudicate clinical endpoints the Banook Group offers a complete and integrated solution based upon a unique set of advanced technologies, the Atrium™ Suite. The suite is an innovative platform specifically designed to build, operate, track and document clinical trials across all study phases from Electronic Data Capture (EDC) to final publications.


Features and benefits of the Atrium platform include:


  • Real time Management, analysis and reporting of centralized data data via a secure web portal,
  • Real time data access and online voting for the adjudication committee members,
  • Dashboard, metrics and executive summary views enables the sponsor/CRO teams to view project status in real time.


Banook Group offers a full range of comprehensive and proactive endpoint adjudication processes and technologies solutions including:


  • Identification, training and coordination of the adjudication committee members,


  • Management of the operational documentation,


  • Set-up and maintenance of an adjudication web portal,


  • Coordination between the investigational sites, sponsor and the adjudication committee,
  • Tracking/follow up and completeness of the adjudication packages,


  • Management of the consensus adjudication meetings,


  • Quality control of the data,


  • Long term archiving of the documentation.